Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

McArthur, Grant A.; Chapman, Paul B.; Robert, Caroline; Larkin, James; Haanen, John B.; Dummer, Reinhard; Ribas, Antoni; Hogg, David; Hamid, Omid; Ascierto, Paolo A.; Garbe, Claus; Testori, Alessandro; Maio, Michele; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; O'Day, Stephen J.; Kirkwood, John M.; Eggermont, Alexander M.; Dreno, Brigitte; Sosman, Jefferey A.; Flaherty, Keith T.; Yin, Ming; Caro, Ivor; Cheng, Suzanne; Trunzer, Kerstin; Hauschild, Axel

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

Autor(en):

McArthur, Grant A.; Chapman, Paul B.; Robert, Caroline; Larkin, James; Haanen, John B.; Dummer, Reinhard; Ribas, Antoni; Hogg, David; Hamid, Omid; Ascierto, Paolo A.; Garbe, Claus; Testori, Alessandro; Maio, Michele; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; O'Day, Stephen J.; Kirkwood, John M.; Eggermont, Alexander M.; Dreno, Brigitte; Sosman, Jefferey A.; Flaherty, Keith T.; Yin, Ming; Caro, Ivor; Cheng, Suzanne; Trunzer, Kerstin; Hauschild, Axel

Tübinger Autor(en):

Garbe, Claus

Erschienen in:

Lancet Oncology (2014), Bd. 15, H. 3, S. 323-332

Verlagsangabe:

Elsevier Science Inc

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/S1470-2045(14)70012-9

ISSN:

1470-2045